Dr. Aaron DeBono is a renowned expert in the field of anti-microtubule agents, with a PhD in Medicinal and Pharmaceutical Chemistry from Monash University.

His research has focused on the re-purposing of Noscapine for cancer treatment and the development of allosteric modulators of Class C GPCRs for conditions like SHPT and Osteoporosis.

With a background in academic research at institutions like CSIRO, BakerIDI, and Drug Discovery Biology MIPS, he has managed various medicinal chemistry programs in areas such as superbugs, malaria, and heart disease.

Dr. DeBono's expertise includes organic chemistry, drug design, SAR, high-throughput screening, and total synthesis, with experience in working with opiates, steroids, natural products, and small molecules.

Apart from his academic roles, he has also been involved in business ventures and start-ups in diverse industries, showcasing his versatility and entrepreneurial spirit.